<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01073514</url>
  </required_header>
  <id_info>
    <org_study_id>TMU-CIH-IR-001</org_study_id>
    <secondary_id>ChiCTR-ONC-00000752</secondary_id>
    <nct_id>NCT01073514</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction</brief_title>
  <acronym>MBOâ€”IR</acronym>
  <official_title>Clinical Trial of Bile Etiology,Proteomics and Metabonomics of Malignant Biliary Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate bile culture and susceptibility test in patients with malignant biliary
      obstruction (MBO) or relation between bile, portal vein or vein culture and biliary
      infection. Also to get the information of bile metabonomics to find potential tumor marker
      .Culture of the organism is recognized as the &quot;gold standard&quot; for diagnosis of infection. Our
      research may be one of the first research on culture and susceptibility test in patients with
      MBO. The results of the trial research will be benefit to experiential therapy of MBO with
      biliary infection and diagnosis of MBO.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will obtain bile sample for culture and susceptibility ,proteomics metabonomics test after
      PTBD. Also get the blood and urine samples.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Malignant Biliary Obstruction</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bile,blood and urine specimen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Malignant obstructive jaundice (MBO)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Those with MBO who can receive Percutaneous Transhepatic Biliary Drainage(PTBD)

        Exclusion Criteria:

          -  Those with MBO who cannot receive Percutaneous Transhepatic Biliary Drainage(PTBD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YU HAI PENG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GUO ZHI, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YU HAI PENG, MD</last_name>
    <phone>13352070835</phone>
    <email>JIERUKE@YAHOO.COM.CN</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institude and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YU HAIPENG, MD</last_name>
      <phone>13352070835</phone>
      <email>JIERUKE@YAHOO.COM.CN</email>
    </contact>
    <investigator>
      <last_name>GUO ZHI, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>YU Haipeng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2010</study_first_submitted>
  <study_first_submitted_qc>February 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2010</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant biliary obstruction (MBO)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

